Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis[3]

New England Journal of Medicine

Volumn 372, Issue 6, 2015, Pages 577-

  Gillespie, Stephen H ^a   Mendel, Carl M ^b   Phillips, Patrick P J ^c  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b TB Alliance   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; BODY MASS; DRUG EFFICACY; DRUG SAFETY; GENE SEQUENCE; HUMAN; LETTER; OUTCOME ASSESSMENT; REINFECTION; TREATMENT INDICATION; TUBERCULOSIS; FEMALE; ISOLATION AND PURIFICATION; MALE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 84922295420     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1414718     Document Type: Letter

References (2)

1. Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacincontaining regimen for treating tuberculosis. N Engl J Med 2014;371:1588-98.
2. Bryant JM, Harris SR, Parkhill J, et al. Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study. Lancet Respir Med 2013;1:786-92.